logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Cancer and Palliative Care

Results

Drugs

April 2019

Nivolumab in combination with cabozantinib for metastatic renal cell carcinoma – first-line

Nivolumab works by improving the activity of white blood cells thereby increasing the ability of the immune system to kill cancer cells. Cabozantinib works to stop signals that cancer cells use to divide and grow. It is thought that when used in combination, both drugs may be more effective than each drug on its own. If licenced, nivolumab in combination with cabozantinib may improve long-term outcomes in mRCC patients who currently have limited treatment options.

Drugs

April 2019

Nivolumab in combination with ipilimumab for oesophageal squamous cell carcinoma – first line

Nivolumab and ipilimumab are immune therapy medicinal products that are currently licensed as a combination treatment of advanced cancers such as melanoma and kidney cancer. Nivolumab works by improving the activity of white blood cells (T-cells) thereby increasing the ability of the immune system to kill cancer cells. Ipilimumab works in a different way but also to increase the activity of T-cells. It is thought that when used together, both drugs may be more effective than each on its own. Both drugs given by injection and the combination may offer a treatment option for patients with advanced, recurrent or metastatic oesophageal squamous cell carcinoma who have not been treated previously.

Drugs

April 2019

Olaparib for BRCAm or ATM mutated metastatic castration-resistant prostate cancer

Olaparib is taken orally and works by blocking a protein called poly [adenosine diphosphate-ribose] polymerase (PARP). PARP is an important protein which tries to fix damaged deoxyribonucleic acid (DNA). By blocking PARP from fixing damaged DNA, the tumour cells may die. If licensed, olaparib will offer an additional treatment option for men with metastatic castrate-resistant prostate cancer with BRCAm or ATM mutations who have progressed following a prior new hormonal agent.

Drugs

March 2019

Durvalumab with or without tremelimumab in addition to platinum based chemotherapy for extensive-stage disease small-cell lung cancer

There are few treatment options available for this condition, and the standard treatment of chemotherapy has not changed for several decades. Durvalumab and tremelimumab are a new kind of treatment for this cancer called immunotherapy that helps the body’s immune system to fight the cancer. These medicinal products are given by intravenous infusion together with chemotherapy. Durvalumab is already licensed in the UK for the treatment of a different type of lung cancer. The combination treatment may be more effective than either treatment alone, and could provide an additional treatment for patients who currently have few effective therapies.

Drugs

March 2019

Nivolumab in combination with rucaparib for metastatic castration-resistant prostate cancer with prior chemotherapy

Nivolumab works by improving the activity of a type of white blood cells called T-cells thereby increasing the ability of the immune system to kill cancer cells. Rucaparib also has anti-tumour activity by blocking the effect of certain enzymes leading to the death of tumour cells. It is thought that when used in combination, both drugs may be more effective than each drug on its own. If licenced, nivolumab in combination with rucaparib may improve long-term outcomes in mCRPC patients who currently have limited treatment options.

Drugs

March 2019

Histamine dihydrochloride (Ceplene) in combination with low dose interleukin-2 as maintenance treatment for acute myeloid leukaemia

Histamine dihydrochloride is an immunostimulant. This means that it changes the activity of the immune system (the body’s natural defences). Histamine is a substance occurring naturally in the body that is involved in many processes. In the treatment of AML, it is thought to work by protecting immune system cells from damage. This improves the effectiveness of IL-2, a medicine that stimulates the immune system to attack cancerous cells. When histamine dihydrochloride is given with IL-2, it helps the immune system to kill the leukaemia cells that may remain in the body during remission. This may increase the likelihood for patients to remain in long-term remission.

Drugs

March 2019

Cediranib in combination with olaparib for recurrent platinum-resistant ovarian cancer – fourth line or greater

Cediranib works by blocking several specific proteins called the vascular endothelial growth factor (VEGF) receptors that are important in the formation of blood vessels to the tumour. Olaparib is a PARP inhibitor which acts by blocking DNA repair leading to the cancer cell death. Olaparib is currently licenced for use in some types of ovarian cancer. Both cediranib and olaparib are taken orally. The combination has demonstrated the potential to act synergistically to improve long-term outcomes in recurrent ovarian cancer patients who currently have limited options beyond third-line treatment.

Drugs

March 2019

Tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 6 to 11 years

Tezacaftor is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del CFTR protein. Ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface. The combination therapy of tezacaftor/ivacaftor-FDC (Symkevi®) has been approved in the EU for patients aged 12 years and older with CF that have this gene mutation. If approved, this licence extension would mean that patients with this gene mutation could have access to this treatment regimen at an earlier age.

Drugs

March 2019

Isatuximab in addition to carfilzomib and dexamethasone for relapsed and/or refractory multiple myeloma

Isatuximab is a monoclonal antibody designed to recognise and attach to a specific target on the surface of cells involved in MM. This action activates certain components of the immune system so that they kill the cancerous plasma cells. Carilzomib combined with dexamethasone is already used for the treatment of MM. The addition of isatuximab to this combination may potentially improve outcomes in patients with relapsed and/or refractory MM who have received other prior therapies.

Drugs

March 2019

Nivolumab in combination with rucaparib for chemotherapy naïve metastatic castration-resistant prostate cancer

Nivolumab works by improving the activity of a type of white blood cells called T-cells thereby increasing the ability of the immune system to kill cancer cells. Rucaparib also has anti-tumour activity by blocking the effect of certain enzymes leading to the death of tumour cells. It is thought that when used in combination, both drugs may be more effective than each drug on its own. If licenced, nivolumab in combination with rucaparib may improve long-term outcomes in mCRPC patients who currently have limited treatment options.

Get Alerts